JP6517833B2 - 神経変性疾患の処置に有用なウィザノライド - Google Patents

神経変性疾患の処置に有用なウィザノライド Download PDF

Info

Publication number
JP6517833B2
JP6517833B2 JP2016554830A JP2016554830A JP6517833B2 JP 6517833 B2 JP6517833 B2 JP 6517833B2 JP 2016554830 A JP2016554830 A JP 2016554830A JP 2016554830 A JP2016554830 A JP 2016554830A JP 6517833 B2 JP6517833 B2 JP 6517833B2
Authority
JP
Japan
Prior art keywords
patient
acid
methyl
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016554830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537432A5 (enExample
JP2016537432A (ja
Inventor
アンソニー エー． ショー，
アンソニー エー． ショー，
ジャン−ピエール ジュリエン，
ジャン−ピエール ジュリエン，
アグネス エイチ． チャン，
アグネス エイチ． チャン，
Original Assignee
イムスター セラピューティクス インコーポレイテッド
イムスター セラピューティクス インコーポレイテッド
ユニバルシテ ラバル
ユニバルシテ ラバル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムスター セラピューティクス インコーポレイテッド, イムスター セラピューティクス インコーポレイテッド, ユニバルシテ ラバル, ユニバルシテ ラバル filed Critical イムスター セラピューティクス インコーポレイテッド
Publication of JP2016537432A publication Critical patent/JP2016537432A/ja
Publication of JP2016537432A5 publication Critical patent/JP2016537432A5/ja
Application granted granted Critical
Publication of JP6517833B2 publication Critical patent/JP6517833B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016554830A 2013-11-25 2014-11-25 神経変性疾患の処置に有用なウィザノライド Expired - Fee Related JP6517833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
US61/908,455 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2016537432A JP2016537432A (ja) 2016-12-01
JP2016537432A5 JP2016537432A5 (enExample) 2018-01-11
JP6517833B2 true JP6517833B2 (ja) 2019-05-22

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554830A Expired - Fee Related JP6517833B2 (ja) 2013-11-25 2014-11-25 神経変性疾患の処置に有用なウィザノライド

Country Status (14)

Country Link
US (1) US10351590B2 (enExample)
EP (1) EP3074414B1 (enExample)
JP (1) JP6517833B2 (enExample)
KR (1) KR20160137945A (enExample)
CN (1) CN105940010B (enExample)
AU (1) AU2014352629B2 (enExample)
BR (1) BR112016012002A2 (enExample)
CA (1) CA2931064C (enExample)
ES (1) ES2728870T3 (enExample)
MX (1) MX364528B (enExample)
PL (1) PL3074414T3 (enExample)
TR (1) TR201905218T4 (enExample)
WO (1) WO2015077780A1 (enExample)
ZA (1) ZA201603117B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
US20210079035A1 (en) * 2017-12-11 2021-03-18 Ethnodyne Compounds for treating neurodegenerative disorders
WO2019116070A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
TW202521103A (zh) * 2023-10-03 2025-06-01 美商恩維達醫療公司 醉茄素a（withaferin a）類似物及使用彼之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Also Published As

Publication number Publication date
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18
EP3074414B1 (en) 2019-01-09
PL3074414T3 (pl) 2019-12-31
BR112016012002A2 (pt) 2017-09-19
ZA201603117B (en) 2020-05-27
US20170022247A1 (en) 2017-01-26
CN105940010B (zh) 2018-03-30
MX364528B (es) 2019-04-30
AU2014352629B2 (en) 2019-03-28
ES2728870T3 (es) 2019-10-29
TR201905218T4 (tr) 2019-05-21
CN105940010A (zh) 2016-09-14
KR20160137945A (ko) 2016-12-02
WO2015077780A1 (en) 2015-05-28
US10351590B2 (en) 2019-07-16
EP3074414A1 (en) 2016-10-05
JP2016537432A (ja) 2016-12-01
AU2014352629A1 (en) 2016-05-26
MX2016006544A (es) 2016-12-12

Similar Documents

Publication Publication Date Title
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
CN106103452B (zh) 皮质抑素类似物及其合成和用途
EA035016B1 (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
CN112047944A (zh) 一种选择性抑制激酶化合物及其用途
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
CN107820495A (zh) 靶向epha4的配体结合域的新型epha4抑制剂
EP4587418A1 (en) Compounds for the treatment of neuromuscular disorders
CA3248640A1 (en) METHODS OF TREATMENT FOR NEURO-INFLAMMATORY DISEASES
CN118510544A (zh) 大麻素类的磷酸酯前药
JP7185226B2 (ja) １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤
WO2022125614A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
JP2026509274A (ja) ソルチリン活性の修飾剤
CN117903092A (zh) 二羟基苯酞类化合物及其制备方法和用途
JP2024507798A (ja) 抗コリンエステラーゼ活性を有する６－メチルウラシル誘導体およびその使用
JP2019532050A (ja) Ｅａａｔ３阻害剤としてのイミダゾール化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190418

R150 Certificate of patent or registration of utility model

Ref document number: 6517833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees